| zurück |
| |||
| allgemeines | South - West Oncology Group | Leitung: Knight Cancer Institute, Portland | Operations Office: San Antonio, Statistik: Seattle. | |
| Über 1000 Tumorstudien | Vom NCI unterstützt. | |||
| SWOG 0500 | Mammakarzinom | zirkulierende Tumorzellen (CTC) | Chemotherapie-Umstellung bei persistierenden CTC unter Chemotherapie | |
| SWOG 0226 | Mammakarzinom | Metastasiert, Östrogenrezeptor-positiv, postmenopausal | Kombination von Anastrozol und Fulvestrant besser als Anastrazol allein. | |
| SWOG-7436 | - Phase III | CMFVP vs Melphalan for operable breast cancer | ||
| SWOG-7827 | - Phase III | |||
| SWOG-8312 | - Phase III Intergroup | |||
| SWOG-8692 | (INT-0075) - Phase III Intergroup | |||
| SWOG-8697 | (INT-0077) - Phase III Intergroup | |||
| SWOG-8807 | - Phase III | |||
| SWOG-8814 | - Phase III | |||
| SWOG-8851 | (INT-0101) (EST-5188) - Phase III Intergroup | CAF vs. CAF+hormonal Tx | ||
| SWOG-8897 | - Phase III Intergroup | CMF vs. CAF ± Tamoxifen in High-Risk, Node Neg. | ||
| SWOG-8931 | (INT-0108) (EST-3189) - Phase III Intergroup | |||
| SWOG-9114 | (INT-0163) (CALGB-9082) - Phase III | Comparason of HD+ABMT vs. Std. Dose AA after CAF I | ||
| SWOG-9313 | - Phase III Intergroup | |||
| SWOG-9332 | - Phase III | |||
| SWOG-9410 | (INT-0148) (CALGB-9344) - Phase III | |||
| SWOG-9412 | - Phase III | Conventional vs. HD Chemo+Stem Cell Transplant | ||
| SWOG-9514 | (EB193) - Phase III Intergroup | Fenretinide vs. placebo with Tamoxifen | ||
| ||||
Impressum .....................................................................................Zuletzt geändert am 14.03.2014 11:34